Regeneron Stock - Weekly review and biotech sector check
19.06.2026 - 22:22:33 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:20 UTC. Details in the imprint.
Regeneron (US75886F1075) is ending the week trading near the $610 level on Nasdaq after a period of consolidation following its first-quarter 2026 earnings beat. As the week closes, investors are taking stock of how the biotech name compares with other large-cap drug developers.
All news and analysis on Regeneron stock
Regeneron’s earnings, pipeline updates and sector moves are covered in our dedicated topic hub.
What the numbers show
Regeneron reported first-quarter 2026 adjusted earnings per share of $9.47, beating the Zacks Consensus Estimate of $8.52 and rising from $8.22 a year earlier. Total revenue climbed 19% year over year to $3.6 billion, driven mainly by Eylea HD and higher Dupixent profit share.
Zacks highlighted that the stronger bottom line was supported by higher sales and a reduced share count, underlining a robust operating performance. Despite the beat, the stock carries a Zacks Rank #3 (Hold), as earnings estimates for the coming periods have been revised cautiously lower.
Friday view and sector comparison
Over the week, Regeneron shares have hovered close to the $610 line, broadly in step with the wider US biotech and pharma complex. According to Nasdaq data cited by several market portals, the stock closed at $609.94 on 06/18/2026, up 0.33% on the day.
That level leaves the company with a multi?billion dollar equity value in the Standard & Poor's 500 index, positioning it among the larger US biotech and specialty pharma names. In relative terms, the move this week has been more muted than some smaller-cap biotech peers, but more stable than many early-stage drug developers.
How the company makes money
Regeneron generates most of its revenue from ophthalmology and immunology medicines, led by retinal drug Eylea HD and asthma and dermatitis treatment Dupixent, which it co?develops with Sanofi. Additional revenue comes from oncology and rare disease franchises, plus collaboration and royalty income.
Where the stock trades today
Regeneron shares (US75886F1075) trade on Nasdaq at about $610.00 as of 06/19/2026, 16:00 Eastern Time, according to recent quote data from major market portals.
Key facts on Regeneron stock
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- WKN: 881535
- Ticker: REGN
- Venue: Nasdaq
- Price (as of 06/19/2026, 16:00 ET): 610.00 USD
- Market cap: around 66,000,000,000 USD (as of 06/19/2026, based on recent prices and reported share count)
- Sector / Industry: Health Care / Biotechnology & Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
